Astrazeneca PLC (NYSE:AZN) received a $38.00 price objective from research analysts at BMO Capital Markets in a report issued on Tuesday. The brokerage currently has a “buy” rating on the stock. BMO Capital Markets’ price target points to a potential upside of 10.14% from the company’s previous close.

A number of other research analysts have also recently issued reports on the stock. BidaskClub cut shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Liberum Capital cut shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. BNP Paribas raised shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Investec raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Finally, Pareto Securities raised shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the company. Astrazeneca PLC presently has an average rating of “Hold” and an average target price of $35.10.

Astrazeneca PLC (NYSE:AZN) traded up 2.16% during midday trading on Tuesday, hitting $34.50. The stock had a trading volume of 5,030,951 shares. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The stock has a market cap of $87.35 billion, a price-to-earnings ratio of 22.63 and a beta of 0.76. The stock has a 50 day moving average of $33.84 and a 200 day moving average of $32.57.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/31/astrazeneca-plc-azn-given-a-38-00-price-target-by-bmo-capital-markets-analysts.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Fisher Asset Management LLC boosted its position in Astrazeneca PLC by 4.7% during the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock worth $393,061,000 after acquiring an additional 519,717 shares during the last quarter. BlackRock Inc. boosted its position in Astrazeneca PLC by 287,844.0% during the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock worth $215,198,000 after acquiring an additional 6,908,257 shares during the last quarter. Federated Investors Inc. PA boosted its position in Astrazeneca PLC by 3.6% during the second quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock worth $152,885,000 after acquiring an additional 156,256 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Astrazeneca PLC by 5.9% during the second quarter. Ameriprise Financial Inc. now owns 2,827,262 shares of the company’s stock worth $96,789,000 after acquiring an additional 157,293 shares during the last quarter. Finally, Voya Investment Management LLC boosted its position in Astrazeneca PLC by 38.2% during the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after acquiring an additional 662,481 shares during the last quarter. Hedge funds and other institutional investors own 14.18% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.